Re­mote FDA drug in­spec­tions: New draft guid­ance spells out post-pan­dem­ic specifics

One of the FDA’s biggest tools from the pan­dem­ic is here to stay, and the agency re­leased new draft guid­ance on how it plans to re­quest and con­duct vol­un­tary re­mote in­spec­tions of fa­cil­i­ties where drugs are man­u­fac­tured, packed, com­pound­ed or held.

The 10-page draft re­leased Wednes­day, which re­places a sim­i­lar draft from April 2021, ex­plains which re­mote in­ter­ac­tive tools the FDA may use to re­quest an in­spec­tion, in­clud­ing but not lim­it­ed to in­spec­tions oc­cur­ring pri­or to a new drug ap­proval, parts of sur­veil­lance drug qual­i­ty in­spec­tions ex­am­in­ing over­all op­er­a­tions, and fol­low-up or com­pli­ance-re­lat­ed in­spec­tions.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER